ThinkEquity appears to expect a potential upside of more than 300% based on current levels. The firm gave its Buy rating on the stock but placed a $10 target. Meanwhile, ThinkEquity has much higher expectations for the penny stock. HC Wainwright started Context with a Buy rating and a $6 price target. This week two firms initiated coverage on CNTX stock. The o-principal investigator, Meritxell Bellet, also explained that “These results support further evaluation of ONA-XR in the treatment of early breast cancer.” CNTX Stock Forecast
Just before year-end, Context revealed data on its ONAWA trial and reported that its ONA-XR platform has the potential to help inhibit tumor spread. At the Biotech Showcase and Edison Group Open House Global Healthcare conferences, the company participated in panel discussions and individual investor meetings.
#STOCKS TO BUY NOW UPDATE#
The most recent update from the company highlighted 2 January conference presentations. The company specializes in women’s oncology therapeutics and develops breast and gynecological cancers treatments. This list of penny stocks is full of biotech names, and Context Therapeutics kicks things off. Penny Stocks To Buy : Context Therapeutics Inc. I’ll leave it up to you to decide if these firms are correct in their expectations or if the risk isn’t worth the potential reward. Today we’ll look at a handful of names that some of them have made bold predictions about based on price targets. Some of the top Wall Street analyst firms take a stab at finding penny stocks to buy. However, with that risk comes the potential for an even greater reward than other, higher-priced stocks.īelieve it or not, penny stocks are researched by more than just retail traders. They’ve come under plenty of scrutinies due to the higher risks involved in trading or investing in them.
Penny stocks are defined as shares of companies trading for under $5.
0 kommentar(er)
